RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb)
Gastro-Oesophageal Cancer

About this trial
This is an interventional treatment trial for Gastro-Oesophageal Cancer focused on measuring Metastatic, Locally recurrent, Oesophago-gastric junction, Stomach, Adenocarcinoma, Undifferentiated carcinoma, RegoNivo
Eligibility Criteria
Inclusion Criteria:
Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal cancer which:
- has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
- is of adenocarcinoma or undifferentiated carcinoma histology; and
- is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrolment; and
- has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue. Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be considered as first line treatment where people have relapsed or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.
- HER2-positive participants must have received trastuzumab
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1).
- Ability to swallow oral medication.
- Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC) ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL).
- Adequate renal function (Creatinine clearance >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN).
Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)).
Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.
- Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
- Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday)
- Signed, written informed consent
Exclusion Criteria:
- Known allergy to the investigational product drug class or excipients in the regorafenib and/or nivolumab
- Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
- Participants with known, uncontrolled malabsorption syndromes
- Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted.
- Any prior use of more than one immune checkpoint inhibitor
- Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
- Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
- Concurrent treatment with strong CYP3A4 inhibitors or inducers.
- Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to < Grade 2 according to CTCAE V5.0
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
- Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
- Venous thrombotic events and pulmonary embolism within 3 months prior to randomization
- Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization.
- Non-healing wound, ulcer, or bone fracture.
- Interstitial lung disease with ongoing signs and symptoms
- Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
- Persistent proteinuria of ≥ Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection.
- Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
History of another malignancy within 2 years prior to randomization. Participants with the following are eligible for this study:
- curatively treated cervical carcinoma in situ,
- non-melanomatous carcinoma of the skin,
- superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]),
- treated thyroid papillary cancer
- Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
- Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment
- Patients with a ≥ grade 3 active infection according to CTCAE version 5.0
- Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease
- Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy; if used as replacement therapy e.g. ≤ 10 mg prednisolone or dexamethasone ≤ 2 mg per day) or immunosuppressants, or who have received such a therapy < 14 days prior to randomisation
- Patients with a seizure disorder who require pharmacotherapy
- Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol.
- Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.
Sites / Locations
- Mayo Clinic ArizonaRecruiting
- USC NorrisRecruiting
- Siouxland Regional Cancer CenterRecruiting
- Monument Health Rapid City HospitalRecruiting
- Fred Hutchinson Cancer Research Centre - South Lake Union ClinicRecruiting
- Coffs Harbour Health CampusRecruiting
- Concord Repatriation General HospitalRecruiting
- St Vincent's Public HospitalRecruiting
- Border Medical Oncology Research UnitRecruiting
- Gosford HospitalRecruiting
- St George HospitalRecruiting
- Newcastle Private HospitalRecruiting
- Port Macquarie Base HospitalRecruiting
- Prince of Wales HospitalRecruiting
- Royal North Shore Private HospitalRecruiting
- The Tweed HospitalRecruiting
- Ballarat Oncology and Haematology ServicesRecruiting
- Westmead HospitalRecruiting
- Royal Darwin HospitalRecruiting
- The Townsville HospitalRecruiting
- Royal Brisbane and Womens HospitalRecruiting
- Sunshine Coast University HospitalRecruiting
- The Queen Elizabeth HospitalRecruiting
- Flinders Medical CentreRecruiting
- Royal Hobart HospitalRecruiting
- Monash HealthRecruiting
- Austin HealthRecruiting
- Sir Charles Gairdner HospitalRecruiting
- St John of God Hospital SubiacoRecruiting
- Landeskrankenanstalten-Betriebsgesellschaft-KABEG
- Ordensklinikum Linz GmbH Barmherzige schwestern
- Medizinische Universitaet Wien
- Landesklinikum Wiener Neustadt
- Evang. Klinikum Bethel BielefeldRecruiting
- Helios Bad SaarowRecruiting
- Klinikum BayreuthRecruiting
- Charité Universitätsmedizin BerlinRecruiting
- Universitätsklinikum Bonn
- KEM/Evang. Kliniken Essen Mitte gGmbHRecruiting
- Institut für Klinisch Onkol Forschung am Krankenhaus NordwestRecruiting
- Universitätsklinikum Greifswald
- Norddeutsches Studienzentrum für Innovative Onkologie (NIO)Recruiting
- Universitätsklinikum HeidelbergRecruiting
- Universitätsklinikum JenaRecruiting
- Kliniken der Stadt KölnRecruiting
- Universitätsklinikum LeipzigRecruiting
- Klinikum Leverkusen gGmbHRecruiting
- Klinikum LudwigburgRecruiting
- Klinikum Magdeburg gGmbHRecruiting
- Universitätsklinikum MainzRecruiting
- Philipps-Universitat MarburgRecruiting
- Klinikum rechts der Isar der TU MünchenRecruiting
- Studienzentrum Onkologie RavensburgRecruiting
- Caritas Klinikum Saarbrücken St. TheresiaRecruiting
- Universitätsklinikum UlmRecruiting
- Istituto Nazionale Tumori di Napoli-IRCCS Fondazione G. Pascale
- Universitae degli studi della Campania "Luigi Vanvitelli"
- Azienda USL-IRCCS Di Reggio Emilia
- San Camillo Forlanini Hospitals
- Universita Cattolica del Sacro Cuore, University Hospital Gemelli
- IRCCS Fondazione Casa Sollievo della Sofferenza
- National Cancer Centre Hospital EastRecruiting
- Hokkaido University HospitalRecruiting
- Kyushu Cancer CenterRecruiting
- Shikoku Cancer CenterRecruiting
- Saitama Cancer CenterRecruiting
- Shizuoka Cancer CenterRecruiting
- Hallym University Sacred Heart Hospital
- Dong-A University Hospital
- Haeundae Paik Hospital
- Chungbuk National University Hospital
- Jeonbuk National University Hospital
- Gyeongsang National University Hospital
- Asan Medical Centre
- Chung-Ang University Hospital
- Kangbuk Samsung Hospital
- Korea University Anam Hospital
- Korea University Guro Hospital
- Seoul National University Bundang Hospital
- Seoul National University Hospital
- SMG-SNU Boramae Medical Center
- The Catholic University of Korea - Seoul St. Mary's Hospital
- The Catholic University of Korea - Yeouido St. Mary's Hospital
- Yonsei University Health System - Gangnam Severance Hospital
- Yonsei University Health System - Severance Hospital
- Vall d'Hebron University Hospital
- Hospital Universitario de Navarra
- Hospital Clinico Universitario De Valencia
- Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
- China Medical University Hospital (CMUH)Recruiting
- National Cheng Kung University HospitalRecruiting
- National Taiwan University Hospital (NTUH)Recruiting
- Taipei Veterans General Hospital (TPVGH)
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
RegoNivo
Standard of Care
Participants in the RegoNivo arm will; self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and; receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion. After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days.
Participants in the control arm will receive investigator choice chemotherapy with any of the following agents taxane (paclitaxel or docetaxel) irinotecan or oral trifluridine/tipiracil (TAS102) All treatment groups will receive Best Supportive Care (BSC).